EVAX vs. PMCB, CHRO, TLPH, KPRX, KLTO, JAGX, BCLI, PHXM, CSCI, and AIMD
Should you be buying Evaxion Biotech A/S stock or one of its competitors? The main competitors of Evaxion Biotech A/S include PharmaCyte Biotech (PMCB), Chromocell Therapeutics (CHRO), Talphera (TLPH), Kiora Pharmaceuticals (KPRX), Klotho Neurosciences (KLTO), Jaguar Health (JAGX), Brainstorm Cell Therapeutics (BCLI), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry.
Evaxion Biotech A/S vs.
Evaxion Biotech A/S (NASDAQ:EVAX) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking.
11.0% of Evaxion Biotech A/S shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 41.6% of Evaxion Biotech A/S shares are held by company insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
PharmaCyte Biotech has lower revenue, but higher earnings than Evaxion Biotech A/S. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks.
Evaxion Biotech A/S currently has a consensus price target of $20.00, indicating a potential upside of 690.51%. Given Evaxion Biotech A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Evaxion Biotech A/S is more favorable than PharmaCyte Biotech.
In the previous week, Evaxion Biotech A/S had 2 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 2 mentions for Evaxion Biotech A/S and 0 mentions for PharmaCyte Biotech. Evaxion Biotech A/S's average media sentiment score of 0.57 beat PharmaCyte Biotech's score of 0.00 indicating that Evaxion Biotech A/S is being referred to more favorably in the media.
Evaxion Biotech A/S has a beta of -0.28, indicating that its stock price is 128% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500.
PharmaCyte Biotech has a net margin of 0.00% compared to Evaxion Biotech A/S's net margin of -347.83%. PharmaCyte Biotech's return on equity of 0.76% beat Evaxion Biotech A/S's return on equity.
Evaxion Biotech A/S received 26 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
Summary
Evaxion Biotech A/S and PharmaCyte Biotech tied by winning 8 of the 16 factors compared between the two stocks.
Get Evaxion Biotech A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evaxion Biotech A/S Competitors List
Related Companies and Tools
This page (NASDAQ:EVAX) was last updated on 2/22/2025 by MarketBeat.com Staff
